Israeli late-stage biopharmaceutical firm PolyPid (Nasdaq: PYPD) has reported optimistic Section III trial outcomes on its therapy for surgical…
Read More
Israeli late-stage biopharmaceutical firm PolyPid (Nasdaq: PYPD) has reported optimistic Section III trial outcomes on its therapy for surgical…
Read More